Phase II Study of Anlotinib in Patients With Advanced Non-small Cell Lung Cancer（ALTER0302）

Exclusion Criteria

• •1. SCLC(including mixed with NSCLC);
• •2. the central cavity of Squamous cell carcinoma and hemoptysis with NSCLC;
• •3. patients failed to use the anti-tumor angiogenesis therapy;
• •4. patients has many influence factors toward oral medications ;
• •5. Brain metastases patients accompanied by symptoms or symptom control for less than two months;
• •6. patients with severe and failed to controlled diseases,including: suboptimal blood pressure control;suffering from myocardial ischemia or above grade I myocardial infarction, arrhythmias and Class I heart failure;activity or failure to control severe infections;liver disease such as cirrhosis, decompensated liver disease, chronic active hepatitis;poorly controlled diabetes (FBG)\>10mmol/L);urine protein≥++,etc.
• •7. patients failed to heal wounds or fractures for Long-term;
• •8. 4 weeks before enrollment, patients appeared NCI CTC AE grading \>1 pulmonary hemorrhage; 4 weeks before enrollment, patients who appeared NCI CTC AE grade\> 2 have other parts of the bleeding; patients has a tendency to bleed (eg active peptic ulcer) or are receiving thrombolytic or anticoagulant therapy such as warfarin, heparin or its analogues;
• •9. patients occurred venous thromboembolic events within 6 months;
• •10. patients has HIV-positive or organ transplantation;